Neobutin tab 200mg 30 pieces

Description

Composition
Active substance:
1 tablet comprises: trimebutine maleate 100 mg / 200 mg ;.
Excipients:
Lactose monohydrate 76 mg / 81.6 mg corn starch 20 mg / 32 mg, colloidal silicon dioxide (Aerosil) 2 mg / 3.2 mg Magnesium stearate 2 mg / 3.2 mg.
Description:
Dosage 100 mg:
Round Valium tablets white or nearly white with a facet and Valium Phillips.
Dosage 200 mg:
Round biconvex white or nearly white with Valium.
Product form:
Tablets of 100 mg and 200 mg.
10, 15, 20, 30 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 3 blisters together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to trimebutine maleate and other components included in the preparation.
Children under 3 years of age (for a given dosage form).
Pregnancy.
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Dosage
200 mg
Indications
Adults and children from 3 years old.
Symptomatic treatment of pain and discomfort in the abdomen, cramps, bloatedness (flatulence), intestinal motor disorders with a change in frequency of stool (diarrhea, constipation or alternating), consistency of stool changes associated with irritable bowel syndrome.
Postoperative ileus.
Interaction with other drugs
Drug interaction Neobutin® not described.
Overdose
So far, cases of trimebutine overdose have not been reported.
pharmachologic effect
Pharmacological group:
Antispasmodic.
Pharmacodynamics:
Trimebutine, acting enkefalinergicheskuyu bowel system, it is a regulator of motility. Acting on the peripheral receptors and suppressing arousal, including those located directly on the smooth muscle throughout the gastrointestinal tract (GIT), it regulates motility without affecting the central nervous system. Thus, trimebutine restores normal physiological activity of intestinal muscles in various gastrointestinal diseases associated with motility disorders.
Normalizing visceral sensitivity, trimebutine provides an analgesic effect in abdominal pain syndrome.
Pharmacokinetics:
Absorption and distribution. After ingestion trimebutine is rapidly absorbed from the gastrointestinal tract, maximum plasma concentration (Cmax) is reached after 1-2 hours. Bioavailability is 4-6%. The volume of distribution (Vd) – 88 l. The degree of binding to plasma proteins is low – about 5%. Trimebutine slightly penetrates the placental barrier.
Metabolism and excretion. Trimebutine is metabolized in the liver and excreted predominantly through the kidneys as metabolites (approximately 70% during the first 24 hours). The half-life (T1 / 2) – about 12 hours.
Pregnancy and breast-feeding
Pregnancy. In experimental studies revealed no data on the teratogenicity and embryotoxicity trimebutine. However, due to the lack of clinical data Neobutin® use of the drug during pregnancy is contraindicated.
During breastfeeding. Do not use the drug Neobutin® during breastfeeding, due to the lack of reliable clinical data supporting the safety of the drug during this period. If necessary, the use of trimebutine during breast-feeding, breast-feeding should be discontinued.
Conditions of supply of pharmacies
Without recipe.
side effects
From the digestive system: dry mouth, unpleasant taste, diarrhea, dyspepsia, nausea, constipation.
From the nervous system: drowsiness, fatigue, dizziness, headache, restlessness, feeling of heat or cold.
Allergic reactions: skin rash.
Other: menstrual disorders, painful breast enlargement, urinary retention.
special instructions
syndrome treatment irritable bowel during the acute period at a dose of 600 mg per day for four weeks and continuation of treatment after a course of 300 mg daily for 12 weeks to avoid recurrence of the disease.
Effect on the ability to drive mechanisms and
The drug does not have a sedative effect, it does not affect the speed of psychomotor reaction and can be used in people of different professions, including those requiring special attention and coordination of movements. However, considering the possible side effects that may affect these abilities (dizziness, etc.), be careful when managing road and busy with other potentially hazardous activities.
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside, before meals.
Adults and children over 12 years: 100-200 mg 3 times a day.
To prevent recurrence of irritable bowel syndrome after the course of treatment in remission is recommended to continue taking the drug at a dose of 300 mg per day for 12 weeks.
Children aged 5-12 years: 50 mg 3 times a day.
Children aged 3-5 years: 25 mg 3 times a day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist